Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NVCT
SellNuvectis Pharma, Inc. · Healthcare · United States · $775M · Avg Vol: $5M/d
COMPANY DESCRIPTION
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for the treatment of cancer. The company focuses on advancing a pipeline of proprietary oncology drug candidates, aiming to address significant unmet needs in various tumor types through targeted approaches and novel mechanisms of action.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.70 | -1.43 | -1.11 | -1.32 | — | -1.32 | -1.00 | -1.13 | — |
| Shares | 31.5M | 17.4M | 19.5M | 25.7M | -18.6% | 32.6M | — | — | — |
| Debt | — | — | — | — | — | — | — | — | — |
| Equity | 14.2M | 12.2M | 9.7M | 18.4M | 9.0% | — | — | — | — |
| Op CF | -13.6M | -16.0M | -12.2M | -16.0M | — | -19.5M | — | — | — |
| Inv CF | 0 | 0 | 0 | 0 | — | — | — | — | — |
| Fin CF | 27.8M | 15.1M | 11.7M | 29.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NVCT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NVCT | Nuvectis Pharma, Inc.(you) | $775M | 27 | Sell |
| AURA | Aura Biosciences, Inc. | $767M | 26 | Sell |
| FDMT | 4D Molecular Therapeutics, Inc. | $810M | 26 | Sell |
| DRUG | Bright Minds Biosciences Inc. | $714M | 25 | Sell |
| CBIO | Crescent Biopharma, Inc. | $659M | 26 | Sell |
| STTK | Shattuck Labs, Inc. | $707M | 24 | Sell |
| VSTM | Verastem, Inc. | $654M | 25 | Sell |
| ACHV | Achieve Life Sciences, Inc. | $834M | 22 | Sell |
| ACRS | Aclaris Therapeutics, Inc. | $885M | 23 | Sell |
| MPLT | MapLight Therapeutics, Inc. | $584M | 26 | Sell |
Peer medians: ROE -24.4% · P/E 31.0x · Gross margin 58.8%